Shandong Wit Dyne Health Co.,Ltd. (SHE:000915)

Market Cap	7.42B +24.8%
Revenue (ttm)	2.36B +10.1%
Net Income	558.24M +14.0%
EPS	2.38 +14.0%
Shares Out	234.33M
PE Ratio	13.30
Forward PE	13.31
Dividend	2.50 (8.07%)
Ex-Dividend Date	Oct 17, 2025

Volume	2,583,816
Average Volume	3,118,404
Open	31.18
Previous Close	31.67
Day's Range	31.16 - 31.78
52-Week Range	27.90 - 36.70
Beta	0.11
RSI	44.63
Earnings Date	Apr 24, 2026

About Shandong Wit Dyne Health

Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company also provides dextran iron granules, oral rehydration salt powder, montmorillonite powder, azithromycin granules, rifaximin dry suspension, and succinate capsules. In addition, it offers information product...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 1,759
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000915

Financial Performance

In 2024, Shandong Wit Dyne Health's revenue was 2.13 billion, a decrease of -14.08% compared to the previous year's 2.48 billion. Earnings were 515.59 million, a decrease of -11.90%.